Trial Profile

A double-blind controlled study Phase Ib/II study of COYA-302 in patients with amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Nov 2024 According to a Coya Therapeutics media release, Upon IND acceptance and first patient dosing of COYA-302 in ALS, eligible to receive milestone payments of $8.4 million from strategic partner, Dr. Reddy's Laboratories (DRL).
06 Nov 2024 According to a Coya Therapeutics media release, submission of additional data to support the start of the COYA-302 Phase 2 trial in patients with ALS anticipated in Q2 2025.
21 Feb 2024 According to Coya media release, the company expanding the pipeline for COYA 302, adding Alzheimers disease (AD) to indications and topline results anticipated in mid-2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com